Statin therapy improves long-term survival in patients with myocardial infarction and non-obstructive coronary

Konrad Stępień1,2, Grzegorz Horosin3, Natalia Kachnic3

  • 1Department of Coronary Artery Disease and Heart Failure, St. John Paul II Hospital, Cracow, Poland.

Insights

Statin therapy in myocardial infarction with non-obstructive coronary arteries (MINOCA) patients was associated with lower long-term mortality. These findings support statin use in MINOCA for improved outcomes.

Area of Science:

  • Cardiology
  • Clinical Research
  • Pharmacology

Background:

  • Guidelines suggest statins for myocardial infarction with non-obstructive coronary arteries (MINOCA), but evidence is limited.
  • Investigating statin's long-term impact on MINOCA patient mortality is crucial.

Purpose of the Study:

  • To evaluate the effect of statin therapy on long-term all-cause mortality in MINOCA patients.
  • To understand factors influencing statin prescription in MINOCA.

Main Methods:

  • Coronary angiography identified 1,011 myocardial infarction patients from 2012-2019.
  • 77 patients were diagnosed with MINOCA (coronary artery narrowing <50%).
  • Clinical data, discharge statin use, and long-term mortality were analyzed.

Main Results:

  • Statin therapy was prescribed to 74% of MINOCA patients at discharge.
  • Statin use was linked to higher rates of hypertension, dyslipidemia, and BMI, and lower rates of active cancer.
  • MINOCA patients not receiving statins had significantly higher long-term all-cause mortality (p=0.025).

Conclusions:

  • Statin prescription in MINOCA is influenced by clinical factors and lipid profiles.
  • Statin therapy is associated with reduced long-term mortality in MINOCA patients.
  • Findings support statin use in MINOCA for improved patient prognosis.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
726
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
443
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.0K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
487